Publication Name	World Journal of Gastroenterology
Manuscript ID	40524
Country	Italy

Received	2018-07-03 02:27
Peer-Review Started	2018-07-03 04:43
First Decision by Editorial Office Director	2018-07-17 17:23
Return for Revision	2018-07-18 07:06
Revised	2018-08-06 18:52
Publication Fee Transferred
Second Decision by Editor	2018-08-20 08:15
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2018-08-24 09:12
Articles in Press	2018-08-24 09:12
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-09-20 08:00
Publish the Manuscript Online	2018-09-25 03:44

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Manuscript Source	Invited Manuscript
All Author List	Giorgia Marisi, Alessandro Cucchetti, Paola Ulivi, Matteo Canale, Giuseppe Cabibbo, Leonardo Solaini, Francesco Giuseppe Foschi, Serena De Matteis, Giorgio Ercolani, Martina Valgiusti, Giovanni Luca Frassineti, Mario Scartozzi and Andrea Casadei Gardini
ORCID	Author(s) ORCID Number Giorgia Marisi http://orcid.org/0000-0003-4012-0042 Alessandro Cucchetti http://orcid.org/0000-0001-5269-1964 Paola Ulivi http://orcid.org/0000-0002-4334-9662 Matteo Canale http://orcid.org/0000-0002-9768-7149 Giuseppe Cabibbo http://orcid.org/0000-0002-0946-3859 Leonardo Solaini http://orcid.org/0000-0002-5031-9285 Francesco Giuseppe Foschi http://orcid.org/0000-0002-8216-0918 Serena De Matteis http://orcid.org/0000-0001-9219-4081 Giorgio Ercolani http://orcid.org/0000-0003-4334-5167 Martina Valgiusti http://orcid.org/0000-0002-9843-3538 Giovanni Luca Frassineti http://orcid.org/0000-0001-9376-0057 Mario Scartozzi http://orcid.org/0000-0001-5977-5546 Andrea Casadei Gardini http://orcid.org/0000-0001-6289-7202
Funding Agency and Grant Number
Corresponding Author	Alessandro Cucchetti, MD, PhD, Adjunct Professor, Surgeon, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Albertoni 15, Granarolo Dell'Emilia 40126, Bologna, Italy. aleqko@libero.it
Key Words	Biomarker; Angiopoietin; Neutrophil-to-lymphocyte ratio; Polymorphisms; Sorafenib; MicroRNA; Adverse events; Hepatocellular carcinoma; Vascular endothelial growth factor
Core Tip	Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma, but after 10 years of research into sorafenib response or resistance, there are still no validated prognostic or predictive factors of response.
Publish Date	2018-09-25 03:44
Citation	Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M, Casadei Gardini A. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? World J Gastroenterol 2018; 24(36): 4152-4163
URL	http://www.wjgnet.com/1007-9327/full/v24/i36/4152.htm
DOI	http://dx.doi.org/10.3748/wjg.v24.i36.4152

Full Article (PDF)	WJG-24-4152.pdf
Full Article (Word)	WJG-24-4152.doc
Manuscript File	40524-Review.doc
Answering Reviewers	40524-Answering reviewers.pdf
Audio Core Tip	40524-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	40524-Conflict-of-interest statement.pdf
Copyright License Agreement	40524-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	40524-Language certificate.pdf
Peer-review Report	40524-Peer-review(s).pdf
Scientific Misconduct Check	40524-Scientific misconduct check.pdf
Scientific Editor Work List	40524-Scientific editor work list.pdf